DM
INFI

Deerfield Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Deerfield Management’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-200,000
Closed -$2.76M – 143
2013
Q4 		$2.76M Buy
+200,000
New +$2.82M 0.14% 83

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Deerfield Management's INFI Position: Q2 2017 in Review

Deerfield Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2017, closing a stake of 1,969,225 shares — an estimated $6.36M sold.

Deerfield Management first reported a position in INFI in Q2 2013 and held it in 15 quarters. The position peaked at $65.2M in Q4 2014. 74 funds tracked by Wall St. Rank hold INFI as of Q2 2017.

  • Deerfield Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Deerfield Management sold 1,969,225 Infinity Pharmaceuticals, Inc. shares in Q2 2017, an estimated $6.36M.
  • Deerfield Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
  • Deerfield Management's Infinity Pharmaceuticals, Inc. position peaked at $65.2M in Q4 2014.
  • 74 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2017.

Based on Deerfield Management's 13F filing for Q2 2017, filed 14 Aug 2017.